Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.

Among the nosocomial pathogens, Pseudomonas aeruginosa is recognized as a major cause of morbidity and mortality. Data on 136 patients with P. aeruginosa bacteremia were retrospectively analyzed to evaluate risk factors for mortality. The median age of the patients was 55 years (range, 15-85 years), 78.7% of the cases were hospital-acquired, and the 30-day mortality rate was 39% (53 of 136 patients). Multivariate analysis demonstrated that risk factors for mortality included severe sepsis, pneumonia, delay in starting effective antimicrobial therapy, and an increasing APACHE II score (all P values <.05). In 123 of the 136 patients (excluding 13 patients treated with inadequate definitive antibiotics), 30-day mortality was 27.7% (13 of 47 patients) in the group of patients who received initially effective empirical antimicrobial therapy, and 43.4% (33 of 76) in the group of patients who received delayed effective antimicrobial therapy (P=.079). There was a trend toward higher mortality as the length of delay increased. Delay in starting effective antimicrobial therapy for P. aeruginosa bacteremia tended to be associated with higher mortality.

[1]  W. Bilker,et al.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  G. Maschmeyer,et al.  Review of the Incidence and Prognosis of Pseudomonas aeruginosa Infections in Cancer Patients in the 1990s , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[3]  H. Sax,et al.  Clinical Impact of an Infectious Disease Service on the Management of Bloodstream Infection , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[4]  G Sherman,et al.  The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. , 2000, Chest.

[5]  G. Samonis,et al.  Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. , 2000, Archives of internal medicine.

[6]  G Sherman,et al.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.

[7]  V. Valtonen,et al.  Factors Associated with Improved Outcome of Pseudomonas aeruginosa Bacteremia in a Finnish University Hospital , 1998, European Journal of Clinical Microbiology and Infectious Diseases.

[8]  M. Giladi,et al.  Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. , 1998, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[9]  J. Gatell,et al.  Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. , 1996, Archives of internal medicine.

[10]  R. H. Lawrence,et al.  Pseudomonas aeruginosa bacteraemia , 1993, The Medical journal of Australia.

[11]  M. Struelens,et al.  Pseudomonas aeruginosa and Enterobacteriaceae bacteremia after biliary endoscopy: an outbreak investigation using DNA macrorestriction analysis. , 1993, The American journal of medicine.

[12]  D. F. Fayed,et al.  Septic shock in critically ill patients: aetiology, management and outcome. , 1993, The Journal of infection.

[13]  L. Leibovici,et al.  Patients at risk for inappropriate antibiotic treatment of bacteraemia , 1992, Journal of internal medicine.

[14]  V. Yu,et al.  Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. , 1989, The American journal of medicine.

[15]  B. Yangco,et al.  CDC definitions for nosocomial infections. , 1989, American journal of infection control.

[16]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.

[17]  J. Gatell,et al.  Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. , 1988, Reviews of infectious diseases.

[18]  S. Hirschman,et al.  Infections associated with transhepatic biliary drainage devices. , 1987, The American journal of medicine.

[19]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[20]  L. Elting,et al.  Pseudomonas bacteremia. Retrospective analysis of 410 episodes. , 1985, Archives of internal medicine.

[21]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .

[22]  D. Armstrong,et al.  Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report. , 1974, The Journal of infectious diseases.

[23]  P. Wiernik,et al.  Significance of Pseudomonas aeruginosa in the patient with leukemia or lymphoma. , 1974, The Journal of infectious diseases.

[24]  P. Carbone,et al.  Pseudomonas pneumonia. A retrospective study of 36 cases. , 1973, The American journal of medicine.

[25]  A. Lerner,et al.  Characteristics of nonbacteremic Pseudomonas pneumonia. , 1968, Annals of internal medicine.

[26]  G. Pizzolo,et al.  Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies. , 1998, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[27]  G. Woods Antibacterial susceptibility tests : Dilution and disk diffusion methods. , 1995 .